تحري حالة المقاومة المضادة لتكدس الصفيحات عند مرضى داء السكري من النمط الثاني باستخدام دواء الكلوبيدوغريل

الملخص EN

Platelet aggregation of 24 patients with type 2 diabetes on clopidogrel therapy for 7 days was evaluated.

The effect of clopidogrel was assessed using system which measures platelet aggregation by light transmittance (optical aggregometry) in platelet-rich plasma in response to an ADP(2X10-4 M).

Clopidogrel non-responders were defined by an inhibition of ADP (2X10-4 M) induced platelet aggregation that was less than 10% when compared to baseline values 7 days after clopidogrel intake.

Patients with an inhibition over 30% were regarded as responders.

We found that 25 % of the patients were non-responders and 75% were responders.

Patients with the highest pretreatment platelet reactivity remained the most reactive at 7 days after treatment.

Compared with clopidogrel-resistant patients, patients who demonstrated effective clopidogrel inhibition had a significantly lower BMI and had statistically significant impact on clopidogrel resistance.

We conclude that a subgroup of patients with type 2 diabetes not adequately respond to clopidogrel, which may correspond to the occurrence of thromboischemic complications.